CY1105942T1 - Sgk3 ως διαγνωστικος και θepαπευτικος στοχος - Google Patents

Sgk3 ως διαγνωστικος και θepαπευτικος στοχος

Info

Publication number
CY1105942T1
CY1105942T1 CY20071100078T CY071100078T CY1105942T1 CY 1105942 T1 CY1105942 T1 CY 1105942T1 CY 20071100078 T CY20071100078 T CY 20071100078T CY 071100078 T CY071100078 T CY 071100078T CY 1105942 T1 CY1105942 T1 CY 1105942T1
Authority
CY
Cyprus
Prior art keywords
sgk3
diagnostic
therapeutic target
sgk2
excretion
Prior art date
Application number
CY20071100078T
Other languages
English (en)
Inventor
Florian Lang
Philip Cohen
Bjorn Friedrich
Original Assignee
Florian Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang filed Critical Florian Lang
Publication of CY1105942T1 publication Critical patent/CY1105942T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Eye Examination Apparatus (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αφορά στην χρησιμοποίηση μίας ουσίας για την ανίχνευση της sgk2 και/ή της sgk3 για την διάγνωση παθήσεων, που έχουν σχέση με μία διαταραγμένη δραστηριότητα διαύλων ιόντων, ιδιαιτέρως διαύλων νατρίου και/ή καλίου. Περαιτέρω περιλαμβάνεται από την εφεύρεση η χρησιμοποίηση μίας δραστικής ουσίας για την αγωγή των ανωτέρω παθήσεων, όπου η δραστική ουσία επηρεάζει την έκφραση και/ή την λειτουργία της sgk2 και/ή της sgk3 και κατά τον τρόπο αυτό ρυθμίζει την απέκκριση Na+ και/ή την απέκκριση Κ+.
CY20071100078T 2000-08-28 2007-01-22 Sgk3 ως διαγνωστικος και θepαπευτικος στοχος CY1105942T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10042137A DE10042137A1 (de) 2000-08-28 2000-08-28 sgk2 und sgk3 als diagnostische und therapeutische Targets
PCT/EP2001/009890 WO2002017893A2 (de) 2000-08-28 2001-08-28 Sgk2 und sgk3 als diagnostische und therapeutische targets

Publications (1)

Publication Number Publication Date
CY1105942T1 true CY1105942T1 (el) 2011-04-06

Family

ID=7653998

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100078T CY1105942T1 (el) 2000-08-28 2007-01-22 Sgk3 ως διαγνωστικος και θepαπευτικος στοχος

Country Status (18)

Country Link
US (1) US20040038882A1 (el)
EP (1) EP1313476B1 (el)
JP (1) JP2004507493A (el)
CN (1) CN1193756C (el)
AT (1) ATE343386T1 (el)
AU (2) AU2001284038B2 (el)
CA (1) CA2419472A1 (el)
CY (1) CY1105942T1 (el)
DE (2) DE10042137A1 (el)
DK (1) DK1313476T3 (el)
ES (1) ES2275713T3 (el)
HK (1) HK1061801A1 (el)
HU (1) HUP0302938A3 (el)
MX (1) MXPA03001739A (el)
PL (1) PL359714A1 (el)
PT (1) PT1313476E (el)
RU (1) RU2310471C2 (el)
WO (1) WO2002017893A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10346913A1 (de) 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
US20070191326A1 (en) * 2004-03-11 2007-08-16 Florian Lang Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
DE102008059133A1 (de) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
US5243397A (en) * 1992-11-25 1993-09-07 Elop-Electrooptics Industries Ltd. Distance measuring system
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US6083920A (en) * 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
DE19708173A1 (de) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Zellvolumenregulierte humane Kinase h-sgk
EP0887081B1 (en) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
EP0965840A4 (en) * 1997-10-08 2001-10-31 Noboru Kaneko METHOD FOR ANALYZING ANNEXIN V IN URINE AND THEIR USE
US6162613A (en) * 1998-02-18 2000-12-19 Vertex Pharmaceuticals, Inc. Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
WO1999061039A2 (en) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for modulating ischemic cell death
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
US7473534B2 (en) * 2002-03-01 2009-01-06 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples

Also Published As

Publication number Publication date
DE50111328D1 (de) 2006-12-07
HK1061801A1 (en) 2004-10-08
RU2310471C2 (ru) 2007-11-20
ATE343386T1 (de) 2006-11-15
DK1313476T3 (da) 2007-02-26
AU2001284038B2 (en) 2007-03-22
US20040038882A1 (en) 2004-02-26
ES2275713T3 (es) 2007-06-16
JP2004507493A (ja) 2004-03-11
HUP0302938A3 (en) 2009-03-02
CA2419472A1 (en) 2003-02-26
CN1193756C (zh) 2005-03-23
PL359714A1 (en) 2004-09-06
EP1313476B1 (de) 2006-10-25
WO2002017893A3 (de) 2003-01-23
HUP0302938A2 (hu) 2003-12-29
EP1313476A2 (de) 2003-05-28
MXPA03001739A (es) 2004-09-27
DE10042137A1 (de) 2002-03-14
AU8403801A (en) 2002-03-13
PT1313476E (pt) 2007-01-31
WO2002017893A2 (de) 2002-03-07
CN1466456A (zh) 2004-01-07

Similar Documents

Publication Publication Date Title
CY1105942T1 (el) Sgk3 ως διαγνωστικος και θepαπευτικος στοχος
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
TR200100411T2 (tr) 2-(Pürin-9-il)-tetrahidrofuran-3,4-diol türevleri.
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
CY1110322T1 (el) Αναστολεις της her3 δραστικοτητας
DE59912774D1 (de) Mittel zur pflege und/oder behandlung von haut und gewebe
EA200000848A1 (ru) Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
CY1106462T1 (el) Συστηματα απελευθερωσης φαρμακου με βαση λιπιδιο για τοπικη εφαρμογη
DOP2008000001A (es) Oxazolidinonas substituidas y su uso
BRPI0414331A (pt) método de destruição de bactéria numa área de tratamento do paciente e composição antimicrobiana de terapia fotodinámica
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE59611341D1 (de) Verwendung von saccharid-konjugaten
UY26269A1 (es) Formulación de sal común y moxifloxacina
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
ATE311464T1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
BR9814214B1 (pt) composição com ácido azeláico.
BR0210994A (pt) Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
ES2180750T3 (es) Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
ATE328899T1 (de) Zellkernlokalisierendes protein für beta-catenin